Citigroup Upgrades Evolent Health to Buy, Lowers Price Target to $6
Benzinga Newsdesk 3 months ago
NewsUpgradesAnalyst RatingsPrice Target
Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.
Citigroup analyst Daniel Grosslight upgrades Evolent Health (NYSE:EVH) from Neutral to Buy and lowers the price target from $6.75 to $6.